{"analyses":[{"ciLowerLimit":"1.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.51","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"3.92","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"5.05","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"20.87","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"10.26","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.6","upperLimit":"9.2","value":"5.0"},{"groupId":"OG001","lowerLimit":"11.3","upperLimit":"22.2","value":"16.0"},{"groupId":"OG002","lowerLimit":"27.8","upperLimit":"38.9","value":"33.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"275"}],"units":"Participants"}],"description":"PRO is an assessment of the participant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets administered orally QD.","id":"OG000","title":"Placebo Phase 3"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib Phase 3"},{"description":"Participants received one 4 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib Phase 3"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 participants with baseline PRO for scalp hair assessment of ≥ 3 and who had evaluable data for this outcome measure. A Non-responder Imputation (NRI) was applied for participants with missing data at the timepoint due to discontinuation or other intercurrent events.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants With Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥ 2 Point Improvement From Baseline Among Participants With a Score of ≥ 3 at Baseline - Phase 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}